Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase 2-studie av effektivitet og sikkerhet av GAL-101, 2 % oftalmisk løsning i ikke-foveal geografisk atrofi sekundært til ikke-neovaskulær AMD (eDREAM)

9. november 2026 oppdatert av: Galimedix Therapeutics Inc

En fase 2, dobbeltmasket, randomisert, multisenter, parallell gruppe, placebokontrollert studie for å undersøke effektiviteten og sikkerheten til GAL-101, 2 %, oftalmisk løsning hos pasienter med ikke-foveal geografisk atrofi sekundært til ikke-neovaskulær alder- relatert makuladegenerasjon: EDREAM-studie

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).

During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.

The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.

Studietype

Intervensjonell

Registrering (Antatt)

110

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Galimedix Inc. c/o Imperial CRS, MD
  • Telefonnummer: +1 (301) 9179191
  • E-post: info@galimedix.com

Studer Kontakt Backup

Studiesteder

      • Yerevan, Armenia, 0048
        • Rekruttering
        • Ophthalmological Center After S.V. Malayan
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lilit Voskanyan, MD, PhD
    • California
      • Beverly Hills, California, Forente stater, 90211
        • Rekruttering
        • Retina-Vitreous Associates Medical Group
        • Hovedetterforsker:
          • David Boyer, MD
        • Ta kontakt med:
      • Walnut Creek, California, Forente stater, 94598
        • Rekruttering
        • Bay Area Retina Associates
        • Hovedetterforsker:
          • Roger Goldberg, MD
        • Ta kontakt med:
    • Maryland
      • Hagerstown, Maryland, Forente stater, 21740
        • Suspendert
        • Cumberland Valley Retina Consultants
      • Bordeaux, Frankrike, 33000
        • Rekruttering
        • Centre Rétine Gallien
        • Ta kontakt med:
        • Hovedetterforsker:
          • Eric Fourmaux, MD
      • Lyon, Frankrike, 69317
        • Rekruttering
        • Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
        • Ta kontakt med:
        • Hovedetterforsker:
          • Laurent KODJIKIAN, MD
      • Marseille, Frankrike, 13008
        • Rekruttering
        • Centre Monticelli Paradis d'Ophtalmologie
        • Ta kontakt med:
        • Hovedetterforsker:
          • François Devin, MD
      • Paris, Frankrike, 75006
        • Rekruttering
        • Centre Ophtalmologique Odéon
        • Ta kontakt med:
        • Ta kontakt med:
          • Favard, MD
        • Hovedetterforsker:
          • Catherine Favard, MD
      • Tours, Frankrike, 37540
        • Rekruttering
        • Centre médico-chirurgical de Touraine
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sam Razavi, MD
      • Tbilisi, Georgia, 0162
        • Rekruttering
        • Akhali Mzera Limited
        • Ta kontakt med:
        • Hovedetterforsker:
          • Shalva Skhirtladze, MD
      • Tbilisi, Georgia, 0186
        • Rekruttering
        • Caucasus Medical Centre LLC
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mikheil Omiadze, MD, PhD
      • Kildare, Irland, W91 W535
        • Rekruttering
        • UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
        • Hovedetterforsker:
          • Eugene Ng, MD
        • Ta kontakt med:
      • Waterford, Irland, X91 DH9W
        • Rekruttering
        • Institute of Eye Surgery (IOES Waterford)
        • Hovedetterforsker:
          • Eugene Ng, MD
        • Ta kontakt med:
      • Jerusalem, Israel, 9112001
        • Rekruttering
        • Hadassah Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Jaouni, MD
      • Tel Aviv, Israel, 6423906
        • Rekruttering
        • Tel Aviv Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Omer Trivizki, MD
    • Milano
      • Milan, Milano, Italia, 20123
        • Rekruttering
        • Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
        • Ta kontakt med:
        • Hovedetterforsker:
          • Stela Vujosevic, MD
      • Milan, Milano, Italia, 20132
        • Rekruttering
        • Unità di Oculistica, IRCCS Ospedale San Raffaele
        • Ta kontakt med:
        • Hovedetterforsker:
          • Francesco Bandello, MD
    • Roma
      • Roma, Roma, Italia, 00184
        • Rekruttering
        • UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mariacristina Parravanno, MD
      • Bonn, Tyskland, 53127
        • Rekruttering
        • Universitäts-Augenklinik Bonn
        • Hovedetterforsker:
          • Kristina Pfau, MD
        • Ta kontakt med:
      • Freiburg im Breisgau, Tyskland, 79106
        • Rekruttering
        • Universitätsklinikum Freiburg Klinik für Augenheilkunde
        • Hovedetterforsker:
          • Hansjuergen Agostini, MD
        • Ta kontakt med:
      • Hanover, Tyskland, 30625
      • Neubrandenburg, Tyskland, 17036
        • Rekruttering
        • Dietrich Bonhoeffer Klinikum
        • Ta kontakt med:
        • Hovedetterforsker:
          • Christian Brinkmann, MD
      • Tübingen, Tyskland, 72076
        • Rekruttering
        • Universitätsklinikum Tübingen, Department für Augenheilkunde.
        • Ta kontakt med:
        • Hovedetterforsker:
          • Felix Reichel, MD
      • Ulm, Tyskland, 89075
        • Har ikke rekruttert ennå
        • UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
        • Ta kontakt med:
        • Hovedetterforsker:
          • Armin Wolf, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

55 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • ≥55 years of age

  • Willing and able to provide written informed consent

  • Willing and able to comply with the study schedule and study assessments

  • Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution

  • BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline

  • Refractive error between +3 and -6 diopters spherical equivalent in the study eye

  • Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline

  • Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center

    1. Well-delineated cumulative GA area between 1.25 and 12.0 mm2
    2. If GA is multifocal, at least 1 lesion ≥1.25 mm2
    3. GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
    4. GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
    5. GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
    6. GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
    7. Area of PRD must be cumulatively between 7.25 and 25.0 mm2

Exclusion Criteria:

  1. Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline

  2. History of laser therapy in the macular region, regardless of indication

  3. History of herpes zoster

  4. Ophthalmic disease or condition that requires or is likely to require surgery during the study period

  5. GA with cumulative area <1.25 mm2

  6. Any GA lesion within 100 µm radius from the center point of the fovea

  7. Axial length >26 mm

  8. Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)

  9. Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period

  10. Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period

  11. Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period

  12. Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period

    Non-study Eye:

  13. BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)

    Either Eye:

  14. History of uveitis

  15. GA secondary to any condition other than non-neovascular AMD

  16. History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline

  17. Underwent investigational treatment for AMD within 6 months before Visit 1a

    General Exclusion Criteria:

  18. History of therapeutic radiation to the cranium

  19. Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients

  20. History of malignant disease

  21. Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period

  22. Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period

  23. Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period

  24. Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data

  25. Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation

  26. Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline

  27. Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: GAL-101 ophthalmic solution

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Placebo komparator: Placebo

Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval

Patient will apply daily 2 eye drops of Placebo at 5 minutes interval

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
Tidsramme: From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF).

From baseline to last on-treatment visit (48 up to 96 weeks)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
Tidsramme: From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT)

From baseline to last on-treatment visit (48 up to 96 weeks)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. januar 2025

Primær fullføring (Antatt)

30. mars 2028

Studiet fullført (Antatt)

30. mai 2028

Datoer for studieregistrering

Først innsendt

23. oktober 2024

Først innsendt som oppfylte QC-kriteriene

24. oktober 2024

Først lagt ut (Faktiske)

26. oktober 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere